首页> 外文期刊>Colloids and Surfaces, B. Biointerfaces >Performance of biodegradable microcapsules of poly(butylene succinate), poly(butylene succinate-co-adipate) and poly(butylene terephthalate-co-adipate) as drug encapsulation systems
【24h】

Performance of biodegradable microcapsules of poly(butylene succinate), poly(butylene succinate-co-adipate) and poly(butylene terephthalate-co-adipate) as drug encapsulation systems

机译:聚丁二酸丁二醇酯,聚丁二酸丁二酸酯-己二酸酯和聚对苯二甲酸丁二酯-己二酸酯的生物可降解微胶囊作为药物封装系统的性能

获取原文
获取原文并翻译 | 示例
       

摘要

Poly(butylene succinate) (PBSu), poly(butylene succinate-co-adipate) (PBSA) and poly(butylene terephthalate-co-adipate) (PBTA) microcapsules were prepared by the double emulsion/solvent evaporation method. The effect of polymer and poly(vinyl alcohol) (PVA) concentration on the microcapsule morphologies, drug encapsulation efficiency (EE) and drug loading (DL) of bovine serum albumin (BSA) and all-trans retinoic acid (atRA) were all investigated. As a result, the sizes of PBSu, PBSA and PBTA microcapsules were increased significantly by varying polymer concentrations from 6 to 9%. atRA was encapsulated into the microcapsules with an high level of approximately 95% EE. The highest EE and DL of BSA were observed at 1% polymer concentration in values of 60 and 37%, respectively. 4% PVA was found as the optimum concentration and resulted in 75% EE and 14% DL of BSA. The BSA release from the capsules of PBSA was the longest, with 10% release in the first day and a steady release of 17% until the end of day 28. The release of atRA from PBSu microcapsules showed a zero-order profile for 2 weeks, keeping a steady release rate during 4 weeks with a 9% cumulative release. Similarly, the PBSA microcapsules showed a prolonged and a steady release of atRA during 6 weeks with 12% release. In the case of PBTA microcapsules, after a burst release of 10% in the first day, showed a parabolic release profile of atRA during 42 days, releasing 36% of atRA.
机译:通过双重乳液/溶剂蒸发法制备聚丁二酸丁二酯(PBSu),聚丁二酸丁二酸共-己二酸酯(PBSA)和聚对苯二甲酸丁二酯-己二酸二丁酯(PBTA)微胶囊。研究了聚合物和聚乙烯醇(PVA)浓度对牛血清白蛋白(BSA)和全反式维甲酸(atRA)的微胶囊形态,药物包封效率(EE)和载药量(DL)的影响。结果,通过将聚合物浓度从6%改变为9%,PBSu,PBSA和PBTA微胶囊的大小显着增加。 atRA以约95%EE的高水平被封装到微囊中。在1%的聚合物浓度下,BSA的最高EE和DL最高,分别为60%和37%。发现4%PVA是最佳浓度,可产生75%的EE和14%的BSA DL。从PBSA胶囊中释放出的BSA最长,第一天释放10%,到第28天结束时稳定释放17%。atRA从PBSu微胶囊中的释放在2周内呈零级分布,在4周内保持稳定的释放率,累计释放率为9%。同样,PBSA微胶囊在6周内显示出atRA的长期稳定释放,释放率为12%。对于PBTA微囊,在第一天突然释放10%后,在42天之内显示出atRA的抛物线释放曲线,释放了36%的atRA。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号